Vasundhara Rasayans Ltd Stock Price Today (NSE: VRL)
Fundamental Score
Vasundhara Rasayans Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Vasundhara Rasayans Ltd share price today is ₹161.55, up +2.02% on NSE/BSE as of 18 June 2026. Vasundhara Rasayans Ltd (VRL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹63.04 (Cr). The 52-week high for VRL share price is ₹220.00 and the 52-week low is ₹100.10. At a P/E ratio of 13.92x, VRL is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 12.59% and a debt-to-equity ratio of 0.14.
Vasundhara Rasayans Ltd Share Price Chart — NSE/BSE Historical Performance
Vasundhara Rasayans Ltd share price chart: -6.07% return over the past month. 52-week high ₹220.00, 52-week low ₹100.10.
Vasundhara Rasayans Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹158.25 | ₹164.90 | ₹158.25 | ₹161.55 | 3.70K (Cr) | |
| ₹164.90 | ₹164.90 | ₹152.85 | ₹158.35 | 21.00K (Cr) | |
| ₹148.90 | ₹148.90 | ₹148.90 | ₹148.90 | 20.37K (Cr) | |
| ₹123.00 | ₹125.95 | ₹122.00 | ₹124.10 | 1.56K (Cr) | |
| ₹122.35 | ₹122.35 | ₹118.35 | ₹120.05 | 877.00 (Cr) | |
| ₹122.25 | ₹125.00 | ₹118.00 | ₹122.35 | 3.80K (Cr) | |
| ₹121.00 | ₹123.80 | ₹121.00 | ₹122.10 | 1.98K (Cr) | |
| ₹118.30 | ₹126.95 | ₹117.95 | ₹123.90 | 2.64K (Cr) | |
| ₹125.00 | ₹125.00 | ₹120.95 | ₹123.40 | 1.84K (Cr) | |
| ₹120.50 | ₹123.90 | ₹115.70 | ₹123.80 | 1.78K (Cr) |
Vasundhara Rasayans Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹164.90 | ₹164.90 | ₹152.85 | ₹161.55 | -2.03% | |
| ₹122.65 | ₹148.90 | ₹115.70 | ₹148.90 | +21.40% | |
| ₹109.80 | ₹139.40 | ₹106.70 | ₹129.30 | +17.76% | |
| ₹128.50 | ₹130.50 | ₹100.10 | ₹105.65 | -17.78% | |
| ₹143.80 | ₹165.00 | ₹122.00 | ₹129.00 | -10.29% | |
| ₹168.00 | ₹178.45 | ₹129.95 | ₹150.95 | -10.15% | |
| ₹206.35 | ₹207.00 | ₹146.30 | ₹170.10 | -17.57% | |
| ₹166.00 | ₹220.00 | ₹163.00 | ₹206.30 | +24.28% | |
| ₹184.45 | ₹188.90 | ₹162.20 | ₹166.60 | -9.68% | |
| ₹179.90 | ₹203.50 | ₹170.40 | ₹179.50 | -0.22% | |
| ₹207.90 | ₹207.90 | ₹168.22 | ₹180.69 | -13.09% | |
| ₹214.00 | ₹216.55 | ₹192.50 | ₹203.00 | -5.14% |
AI Research Briefing
Powered by Gemini · 2026-04-10
Cheap microcap antacid API manufacturer; liquidity risk and limited upside make it a pass.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. The share price is , down 56.9% from its 52-week high of Recent news is limited to general pharma industry updates and routine corporate filings.
CORE STORY (THE REAL GAME)
Vasundhara Rasayans is an API manufacturer focused on antacids. The market appears to be pricing it as a generic API play, heavily reliant on continued low-cost production and stable demand in a competitive market. The real game is whether they can move up the value chain or expand into higher-margin APIs.
- Cheap valuation
- High promoter holding
- Dividend yield provides some support
- New high-margin API contracts
- Significant expansion of manufacturing capacity
- Acquisition by a larger pharma player
- Microcap liquidity risk
- Negative free cash flow
- Dependence on commoditized antacid APIs
Promoter holding steady at 61.98%, no FII/DII interest.
Indian pharma exports are growing, but pricing pressures and trade uncertainties remain.
No; Free Cash Flow 5Y: ₹-1.28 Cr.
Expect continued slow growth in the antacid API market. Upside is limited unless they diversify or get acquired.
Primary Thesis Risk
Inability to diversify from low-margin antacid APIs will lead to stagnation or decline.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Vasundhara Rasayans Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Vasundhara Rasayans Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of VRL across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Excellent ROCE Performance (16.56%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 13.92 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (40.14%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Conservative Debt Levels (D/E: 0.14)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (17.68x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (61.98%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Revenue Contraction (-9.82%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Negative Free Cash Flow (₹-1.28 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Vasundhara Rasayans Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Vasundhara Rasayans Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
49.4/100 | ₹161.55₹162 | ₹63.04₹63.04 | 13.92Average 13.9 Average | 12.59%Average 12.59% Average | 16.56%Good 16.56% Good | 0.14Excellent 0.1 Excellent | 7.72%Good 7.72% Good | 9.93%Good 9.93% Good | 1.01% | |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Vasundhara Rasayans Ltd PE Ratio History
Historical price-to-earnings ratio for VRL — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹18.44 | ₹290.50 | 15.8x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Vasundhara Rasayans Ltd Dividend History
Annual cash dividends paid by VRL — dividend yield 1.01%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹0.64 Cr |
| FY 2024 | ₹0.64 Cr |
| FY 2023 | ₹0.32 Cr |
| FY 2022 | ₹0.48 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Vasundhara Rasayans Ltd Quarterly Performance
Latest quarterly metrics for VRL — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-9.82%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
40.14%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
9.93%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
7.72%
Compounded annual net profit growth over 5 years
Vasundhara Rasayans Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for VRL — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Vasundhara Rasayans Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Vasundhara Rasayans Ltd (VRL) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Vasundhara Rasayans Ltd
About VRL (Vasundhara Rasayans Ltd)
Vasundhara Rasayans Ltd is a distinguished pharmaceutical manufacturer, specializing in the development, production, and global distribution of high-quality Active Pharmaceutical I...ngredients (APIs), particularly within the critical antacid therapeutic category. With a steadfast commitment to excellence and innovation, VRL caters to the ever-evolving needs of the pharmaceutical industry, supplying a comprehensive portfolio of antacid APIs renowned for their purity, efficacy, and adherence to stringent regulatory standards. Beyond simple manufacturing, VRL positions itself as a strategic partner to its clients, providing extensive technical support and collaborative solutions that ensure the seamless integration of its APIs into diverse pharmaceutical formulations. At the heart of VRL's product offerings lies a diverse array of antacid APIs, meticulously crafted to meet the varying demands of pharmaceutical manufacturers worldwide. This includes aluminum hydroxide gel, magnesium hydroxide, magaldrate, magnesium trisilicate, and aluminum phosphate, each meticulously manufactured to ensure optimal performance and safety. Moreover, VRL's commitment to pushing boundaries is showcased through its specialized offerings like aluminum hydroxide gel with low heavy lead content for sensitive applications, as well as advanced products tailored for lake color applications and aluminum hydroxide amorphous. The company distinguishes itself through a holistic approach, integrating manufacturing expertise with a focus on sustainability and responsible production practices. VRL aims to deliver exceptional value to its customers by providing not just APIs, but also a full range of support services, including formulation assistance, regulatory guidance, and customized solutions. By continually investing in research, technology, and its people, Vasundhara Rasayans Ltd is poised to further strengthen its position as a trusted and reliable partner in the global pharmaceutical landscape.
Company Details
Key Leadership
Corporate Events
Latest News
VRL Share Price: Frequently Asked Questions
What is the current share price of Vasundhara Rasayans Ltd?
Vasundhara Rasayans Ltd (VRL) trades at ₹161.55 on NSE and BSE. Market cap ₹63.04 (Cr). Educational data only.
What is the P/E ratio of Vasundhara Rasayans Ltd?
Vasundhara Rasayans Ltd has a P/E of 13.92x vs industry average 31.77x.
What is the Bull Run score for Vasundhara Rasayans Ltd?
Vasundhara Rasayans Ltd has a Bull Run score of 49.4/100 based on 25+ financial parameters.
Does Vasundhara Rasayans Ltd pay dividends?
Vasundhara Rasayans Ltd has a dividend yield of 1.01%. Past dividends don't guarantee future payments.
What is the ROE of Vasundhara Rasayans Ltd?
Vasundhara Rasayans Ltd has ROE of 12.59%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Vasundhara Rasayans Ltd?
Vasundhara Rasayans Ltd has debt-to-equity of 0.14.
Is Vasundhara Rasayans Ltd a good investment?
Bull Run gives Vasundhara Rasayans Ltd a score of 49.4/100. This is not investment advice — consult a SEBI-registered advisor.